Karen O Jones

Learn More
2-Acetoxy-5-(alpha-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (prasugrel) is a novel thienopyridine prodrug with demonstrated inhibition of platelet aggregation and activation. The biotransformation of prasugrel to its active metabolite, 2-[1-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4-mercapto-3-piperidinylidene]acetic(More)
The pharmacokinetics (PK) and hepatic extraction (E(H)) of human PTH (1-34), hPTH (1-34), were characterized in rat, dog, and monkey, following intraportal (IPO) and intravenous (IV) bolus administration. hPTH (1-34) was administered to Sprague-Dawley rats (2, 10, 100 microg/kg), beagle dogs (3, 6 microg/kg), and rhesus monkeys (6, 30 microg/kg). Serum(More)
A comparative study was made of 2 thromboplastins, the Australasian Reference Thromboplastin, and Simplastin, in a large group of patients on long-term Warfarin therapy. 373 individual samples were obtained. Calibration constants were obtained for those patients with prothrombin ratios within the therapeutic range, and for those well outside the therapeutic(More)
The prothrombin time, activated partial thromboplastin time, thrombin time, and skin bleeding time, with assays of factors II, VII, IX, and X, platelet count, and liver function tests were performed on a group of patients receiving long term warfarin therapy. There were 17 bleeding patients and 13 non-bleeding patients. A study was made, using the(More)
  • 1